HK1208159A1 - Sorcs1 for use in the treatment of obesity and overweight - Google Patents

Sorcs1 for use in the treatment of obesity and overweight Download PDF

Info

Publication number
HK1208159A1
HK1208159A1 HK15108775.7A HK15108775A HK1208159A1 HK 1208159 A1 HK1208159 A1 HK 1208159A1 HK 15108775 A HK15108775 A HK 15108775A HK 1208159 A1 HK1208159 A1 HK 1208159A1
Authority
HK
Hong Kong
Prior art keywords
sorcs1
obesity
fragments
nucleic acid
overweight
Prior art date
Application number
HK15108775.7A
Other languages
English (en)
Chinese (zh)
Inventor
Karen-Marie Pedersen
Anders Nykjaer
Mads Fuglsang KJØBY
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of HK1208159A1 publication Critical patent/HK1208159A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15108775.7A 2012-04-17 2013-04-17 Sorcs1 for use in the treatment of obesity and overweight HK1208159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270191 2012-04-17
DKPA201270191 2012-04-17
PCT/DK2013/050107 WO2013156031A2 (en) 2012-04-17 2013-04-17 SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT

Publications (1)

Publication Number Publication Date
HK1208159A1 true HK1208159A1 (en) 2016-02-26

Family

ID=49384162

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108775.7A HK1208159A1 (en) 2012-04-17 2013-04-17 Sorcs1 for use in the treatment of obesity and overweight

Country Status (10)

Country Link
US (1) US20150166629A1 (https=)
EP (1) EP2874646A4 (https=)
JP (1) JP2015514726A (https=)
CN (1) CN104470532A (https=)
AU (1) AU2013248727A1 (https=)
CA (1) CA2870211A1 (https=)
HK (1) HK1208159A1 (https=)
IL (1) IL235066A0 (https=)
SG (1) SG11201406455YA (https=)
WO (1) WO2013156031A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136781B (zh) * 2015-08-13 2018-03-30 上海交通大学医学院附属瑞金医院 脂肪因子grem2作为药物靶点在治疗肥胖症药物中的应用
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
KR100773323B1 (ko) * 2000-01-10 2007-11-05 맥시겐 홀딩스 리미티드 지-씨에스에프 접합체
CA2498476A1 (en) * 2002-09-09 2004-03-18 Wisconsin Alumni Research Foundation Type 2 diabetes susceptibility genes
RS60019B1 (sr) * 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
EP2440233B1 (en) * 2009-06-10 2016-07-13 Aarhus Universitet Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto

Also Published As

Publication number Publication date
IL235066A0 (en) 2014-12-31
WO2013156031A3 (en) 2013-12-12
EP2874646A4 (en) 2016-07-06
EP2874646A2 (en) 2015-05-27
CN104470532A (zh) 2015-03-25
JP2015514726A (ja) 2015-05-21
AU2013248727A1 (en) 2014-11-06
WO2013156031A2 (en) 2013-10-24
US20150166629A1 (en) 2015-06-18
CA2870211A1 (en) 2013-10-24
SG11201406455YA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
IN2015DN02826A (https=)
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MY171038A (en) Bispecific antigen binding molecules
MX344521B (es) Aminas heterociclicas y sus usos.
PH12014500348A1 (en) Genes and proteins for alkanoyl-coa synthesis
WO2011083150A3 (en) Obesity small molecules
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
IL226127A0 (en) A compound containing hydrolyzed proteins and an oligosaccharide for the treatment of skin diseases
MX2015013749A (es) Metodos para aumentar la sintesis de proteinas musculares despues de entrenamiento simultáneo.
PH12015502126A1 (en) Human pac1 antibodies
MX363465B (es) Tratamiento de la grasa submental.
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
IN2013MN01394A (https=)
SG10201909382UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
LT2859092T (lt) Terapinė vakcina, skirta vaikų 1 tipo diabeto gydymui, ląstelių sorterio taikymas ir treg ląstelių dauginimo būdas, siekiant gaminti terapinę vakciną 1 tipo diabeto gydymui
HK1212554A1 (zh) 給予利福昔明用於重量減輕和肥胖治療的方法
WO2013072163A3 (de) Haarpflegemittel mit antischuppenmitteln und kationischen silikonen
LU91877B1 (en) Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy
WO2013156031A3 (en) SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
MX337139B (es) Composicion de miel con l-alanil-l-glutamina.
IL230751A0 (en) New peptides, preparations containing them and used in methods to treat metabolic, cardiac and immune diseases
WO2013066481A3 (en) Cosmetic use of n-heteroarylbisamide analogs and related compounds
WO2012001329A3 (fr) Utilisation d'un extrait naturel de marc de raisin pour stimuler les defenses naturelles de plantes